Clovis Oncology (CLVS) Tops Q2 EPS by 3c
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 4/19/2024
- Stocks rattled, Treasuries rally after Israel attacks Iran
- Netflix Q1 earnings top estimates on blowout subscriber growth
- Gold prices rally past $2,400 on reports of Israel strikes on Iran
- Oil surges as reports of Israeli strike on Iran roil markets
- Reports of Israeli attack on Iran spark rush to Swiss franc and yen
- Tritium DCFC Limited (DCFC): Three Australian subsidiaries were determined to be insolvent or likely to become insolvent
- Hasbro (HAS) Announces Resignation of Cynthia Williams, President of Wizards of the Coast and Hasbro Gaming
- Frontier Communications (FYBR) says third party had gained unauthorized access to portions of its information technology environment
- Ibotta (IBTA) Prices 6.56M Share IPO at $88/sh
- Netflix (NFLX) Tops Q1 EPS by 77c, Offers Guidance
- After-hours movers: Netflix, Intuitive Surgical, Nordstrom, KB Home
- Midday movers: Tesla, Blackstone, Las Vegas Sands fall; DR Horton rises
- After-hours movers: Alcoa rises; Equifax and Las Vegas Sands fall
- Midday movers: Travelers, JB Hunt fall; United Airlines rises
- After-hours movers: United Airlines, J.B. Hunt, and more
Clovis Oncology Announces Q2 2016 Operating Results and Corporate Update
August 8, 2016 4:05 PM EDTRucaparib NDA submission completed in late June for treatment of patients with advanced ovarian cancer with deleterious BRCA mutated tumors FDA decision on filing and determination of PDUFA date is anticipated in late August Rucaparib MAA submission on track for Q4 2016 Rucaparib NDA dataset accepted for an oral presentation at ESMO 2016 Congress in October Clovis preparing for potential U.S. commercial launch of rucaparib ARIEL3 pivotal rucaparib maintenance study enrollment completed; data now expected in Q4... More
